Related Experiment Video
Updated: Apr 6, 2026
11:13
Porcine Model of Infrarenal Abdominal Aortic Aneurysm
Published on: November 21, 2019
10.0K
PPAR-γ agonist attenuates inflammation in aortic aneurysm patients
Tatsuo Motoki1, Hirotsugu Kurobe2, Yoichiro Hirata3
1Department of Cardiovascular Surgery, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
General Thoracic and Cardiovascular Surgery
|July 28, 2015
Summary
Peroxisome proliferator-activated receptor (PPAR)-γ agonist reduced inflammation and macrophage infiltration in aortic aneurysm patients. This suggests PPAR-γ agonists may help prevent or delay aortic aneurysm progression.
Area of Science:
- Cardiovascular Research
- Inflammation Biology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor (PPAR)-γ agonists, known for anti-diabetic and anti-inflammatory effects, are investigated for cardiovascular benefits.
- Cytokines from adipose tissue contribute to atherosclerosis and aortic aneurysm (AA) development.
- Previous research indicates PPAR-γ agonists can suppress coronary atherosclerosis progression.
Purpose of the Study:
- To evaluate the anti-inflammatory effects of PPAR-γ agonists in the aortic tissue of patients diagnosed with aortic aneurysm (AA).
Main Methods:
- A study involving 16 patients with AA, divided into a PPAR-γ agonist group (n=6) and a control group (n=10).
- The PPAR-γ agonist group received 15 mg/day for over 2 months prior to surgery.
- Biopsy specimens from various fat tissues and the aneurysmal wall were analyzed using histology, immunohistochemistry, and RT-PCR for inflammatory markers.
Main Results:
- PPAR-γ agonist administration significantly decreased macrophage infiltration in the aortic wall and periaortic fat.
- Adiponectin expression increased significantly in subcutaneous and retroperitoneal fat in the PPAR-γ agonist group.
- Expressions of tumor necrosis factor (TNF)-α and matrix metalloproteinase (MMP)-9 were significantly reduced in the aneurysmal wall and periaortic fat of the PPAR-γ agonist group.
Conclusions:
- The findings suggest that PPAR-γ agonists may offer a therapeutic strategy for preventing or slowing the progression of aortic aneurysms.
- Further research is necessary to fully elucidate the detailed effects of PPAR-γ agonists in this context.
More Related Videos
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
552
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
552
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:09GPCRs Regulate Adenylyl Cylase Activity
8.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K